Promedior is a product-focused biopharmaceutical company developing novel therapeutics for the treatment of fibrotic disorders and diseases. Promedior has license to novel biology and is developing innovative new compounds and therapies based on that biology. With management and advisors on the cutting edge of fibrosis research, Promedior is positioned to be the leader in the development of new therapies for fibrotic disorders and diseases. The management team has broad and deep drug development expertise, including global pharmaceutical development, regulatory affairs, clinical development, drug manufacturing and commercialization. Our scientific advisory board is comprised of prominent fibrosis experts from the nation's leading medical centers and universities. A Series A private equity financing co-led by Polaris Venture Partners and Morgenthaler Ventures and joined by HealthCare Ventures and Easton Capital was completed in 2006.
